Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women

Inclusion Criteria

• Only female patients are eligible
• Patients must be 18 years of age or older
• Patients must have Androgenic Alopecia Grade I-II by Ludwig Classification
• Patients must have been on stable birth control if premenopausal.
• Patients are able and willing to provide written informed consent after the nature of the study is fully explained

Exclusion Criteria

• Patients with clinically abnormal hematology, serum chemistry, or screening laboratory results as reviewed by the Principal Investigator
• Patients who have undergone topical and systemic therapies for hair loss 3 months prior to the procedure
• Patients who have used any cosmetic product meant to address hair loss 3 months prior to enrollment
• Patients taking anti-rheumatic disease medication (including methotrexate or other anti-metabolites) within the 3 months prior to study entry.
• Patients previously having undergone hair transplant surgery prior to study entry
• Patients who are pregnant or currently breast-feeding children as Rogaine for Women is contra indicated for these women
• Patients who have taken spironolactone in the 3 months prior to study participation
• Patients with systemic, rheumatic or inflammatory disease or who are immunosuppressed
• Patients with ongoing infectious disease, including HIV and hepatitis
• Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer, or diabetes
• Patients participating in a study of an experimental drug or medical device within 30 days of study entry
• Patients with history of platelet disorders, bone marrow aplasia, sepsis, or cancer in the last 5 years.
• Patients taking antiaggregating therapy
• Patients on anticoagulant therapy
• Patients with tendency to keloid formation
• Patients with uncompensated diabetes
• Patients with active skin disease or skin infection at intended treatment areas